CUSIP: 74373B109
Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
11,324,447
-
Share change
-
-9,866,004
-
Total reported value
-
$25,803,825
-
Put/Call ratio
-
62%
-
Price per share
-
$2.28
-
Number of holders
-
47
-
Value change
-
-$626,053
-
Number of buys
-
30
-
Number of sells
-
21
Quarterly Holders Quick Answers
What is CUSIP 74373B109?
CUSIP 74373B109 identifies PTI - PROTEOSTASIS THERAPEUTICS IN - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q1 2020
-
Previous quarter:
Q3 2019
Recent filing periods for CUSIP 74373B109:
Institutional Holders of PROTEOSTASIS THERAPEUTICS IN - COM (PTI) as of Q4 2019
As of 31 Dec 2019,
PROTEOSTASIS THERAPEUTICS IN - COM (PTI) was held by
47 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
11,324,447 shares.
The largest 10 holders included
SPHERA FUNDS MANAGEMENT LTD., VANGUARD GROUP INC, BlackRock Inc., MACQUARIE GROUP LTD, Bain Capital Public Equity Management II, LLC, WINTON GROUP Ltd, OXFORD ASSET MANAGEMENT LLP, HarbourVest Partners LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
47
institutional shareholders reporting positions in this security
for the Q4 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.